HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Girodon, F. Articles by Praloran, V. Search for Related Content PubMed PubMed Citation Articles by Girodon, F. Articles by Praloran, V.

JAK2V^617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit

François Girodon^*,, Eric Lippert^°, Pascal Mossuz^#, Irène Dobo^@, Nathalie Boiret-Dupré, Jean-François Lesesve, Sylvie Hermouet^**, Vincent Praloran^°

^* Laboratoire d’Hématologie, CHU de Dijon, Dijon, France
^° Laboratoire d’Hématologie, CHU de Bordeaux, Bordeaux, France
^# Laboratoire d’Hématologie, CHU de Grenoble, Grenoble, France
^@ Laboratoire d’Hématologie, CHU d’Angers, Angers, France
Laboratoire d’Hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
Laboratoire d’Hématologie, CHU de Nancy, Nancy, France
^** Laboratoire d’Hématologie, CHU de Nantes, Nantes, France

Correspondence: François Girodon, Laboratoire d’Hématologie, Hôpital du Bocage, CHU de Dijon, Dijon, France. Phone: international +33.380293047. Fax: international +33.380293660. E-mail: francois.girodon{at}chu-dijon.fr

The predictive values of common biological criteria for the diagnosis of polycythemia vera were studied in a cohort of patients with high hematocrit. We found JAK2V^617Fand erythropoietin assays were the most relevant first tests. Classification of patients according to their JAK2V^617F status and erythropoietin levels facilitated the choice of further diagnostic investigations.

Key words: erythrocytosis, polycythemia vera, JAK2V^617F, erythropoietin, myeloproliferative disorders.

This article has been cited by other articles:

				F. Girodon, C. Schaeffer, C. Cleyrat, M. Mounier, I. Lafont, F. D. Santos, A. Vidal, M. Maynadie, and S. Hermouet Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy Haematologica, November 1, 2008; 93(11): 1723 - 1727. [Abstract] [Full Text] [PDF]

				D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood, February 1, 2008; 111(3): 1686 - 1689. [Abstract] [Full Text] [PDF]